Grandfield & Dodd LLC Buys New Position in Zimmer Biomet Holdings, Inc. $ZBH

Grandfield & Dodd LLC acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,539 shares of the medical equipment provider’s stock, valued at approximately $993,000.

Other large investors have also bought and sold shares of the company. Main Management ETF Advisors LLC boosted its position in shares of Zimmer Biomet by 1.0% during the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after purchasing an additional 112 shares in the last quarter. Citizens National Bank Trust Department grew its position in Zimmer Biomet by 17.6% during the 1st quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after purchasing an additional 141 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in Zimmer Biomet by 0.8% during the fourth quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock valued at $1,831,000 after buying an additional 152 shares during the period. TD Private Client Wealth LLC increased its holdings in shares of Zimmer Biomet by 15.3% in the 4th quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock valued at $104,000 after purchasing an additional 153 shares during the period. Finally, Leonteq Securities AG increased its stake in Zimmer Biomet by 5.3% in the 1st quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock valued at $277,000 after buying an additional 153 shares during the period. Institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the completion of the sale, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.28% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on ZBH. Wall Street Zen lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Canaccord Genuity Group raised their target price on shares of Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research note on Monday, August 10th. Citigroup dropped their price target on Zimmer Biomet from $95.00 to $93.00 and set a “neutral” rating on the stock in a research report on Thursday, May 28th. UBS Group reaffirmed a “buy” rating and set a $120.00 price objective on shares of Zimmer Biomet in a research report on Thursday, August 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $104.42.

Zimmer Biomet Stock Performance

NYSE:ZBH opened at $98.13 on Tuesday. The firm has a 50 day moving average of $91.72 and a 200-day moving average of $90.65. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $108.29. The stock has a market capitalization of $18.72 billion, a P/E ratio of 23.88, a price-to-earnings-growth ratio of 3.20 and a beta of 0.45.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $2.01 by $0.06. The company had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.53 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.